Article · 17 Mar 2025
Conference abstractPublished 3 Feb 2020
Anthracycline induced early cardiotoxicity in a very young Omani patient with Acute Myeloid Leukemia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Anthracycline-cardiomyopathy is of concern in children treated for acute myeloid leukemia (AML) as it may be progressive and fatal. It can present as early cardiac dysfunction with onset during or after chemotherapy. Objective: We aim to highlight the risk of early-onset cardiotoxicity with a low cumulative anthracycline dose in a child with AML with concurrent sepsis. Material and Methods: Two-year old Omani boy with AML-M7 with complex karyotype, baseline echocardiography anatomically normal heart with left ventricular ejection fraction (LVEF) 55-60% was planned for chemotherapy. He was initiated on antibiotics (febrile neutropenia guidelines) for high grade fever. Septic work-up was unremarkable, chemotherapy was initiated in second week. Repeat echocardiography revealed no vegetation and an LVEF of 55%. By end of second week, chemotherapy was continued. After second dose of daunorubicin, patient developed tachycardia, tachypnea, respiratory distress, desaturation with a brief seizure terminating in bradycardia and hypotension requiring resuscitation and ventilation. He had LVEF of 30%, was hypertensive, milrinone, dobutamine were initiated, later shifted to frusemide, spironolactone and captopril; digoxin was added as cardiac function remained depressed. Remainder of daunorubicin was skipped. Post-induction BMA revealed remission. Patient received three more courses of anthracycline-free chemotherapy. Prior to course three chemotherapy, patient had another cardiac arrest. Echocardiography one month later revealed global dyskinesia and LVEF of 40-45%. Patient is on regular cardiac monitoring, currently on frusemide, spironolactone, captopril and digoxin at six months follow-up. Results: Refer Table 1 Conclusion: We conclude that in presence of other known risk factors for cardiac dysfunction like severe sepsis, there is probably no risk-free dose of anthracycline; decline in cardiac function may occur early in therapy even after a small cumulative dose requiring close monitoring of cardiac status during chemotherapy. Association of other risk factors need to be explored by evaluation of larger cohort of such patients.
Keywords
Subjects
Nursing & HealthcareAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nursing Research and Practice.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nursing Research and Practice
- SubjectNursing & Healthcare
- BylineArticles whose byline prints “Surekha Tony”
